SP777 SHOULD WE ASSESS COMBINATION OF CYP3A5 AND MDR-1 GENE POLYMORPHISMS TO OPTIMISE TACROLIMUS DOSE IN RENAL TRANSPLANT …
METHODS: We recruited 248 renal transplant recipients (mean age 36.48±10.54; male
(83.47%), all on Tac; MMF and prednisone in the study. Of the 248 patients; 110 had CGN; …
(83.47%), all on Tac; MMF and prednisone in the study. Of the 248 patients; 110 had CGN; …
[PDF][PDF] SP777 SHOULD WE ASSESS COMBINATION OF CYP3A5 AND MDR-1 GENE POLYMORPHISMS TO OPTIMISE TACROLIMUS DOSE IN RENAL …
N Prasad, J Akhilesh, A Vikas - academia.edu
CONCLUSIONS: Our study suggests that an intensive induction immunosuppressive
therapy using PE and rituximab during early post-transplantation period does not decrease …
therapy using PE and rituximab during early post-transplantation period does not decrease …
SP777 SHOULD WE ASSESS COMBINATION OF CYP3A5 AND MDR-1 GENE POLYMORPHISMS TO OPTIMISE TACROLIMUS DOSE IN RENAL TRANSPLANT …
N Prasad, J Akhilesh, A Vikas - Nephrology Dialysis …, 2019 - academic.oup.com
CONCLUSIONS: Our study suggests that an intensive induction immunosuppressive
therapy using PE and rituximab during early post-transplantation period does not decrease …
therapy using PE and rituximab during early post-transplantation period does not decrease …
[PDF][PDF] SP777 SHOULD WE ASSESS COMBINATION OF CYP3A5 AND MDR-1 GENE POLYMORPHISMS TO OPTIMISE TACROLIMUS DOSE IN RENAL …
N Prasad, J Akhilesh, A Vikas - researchgate.net
CONCLUSIONS: Our study suggests that an intensive induction immunosuppressive
therapy using PE and rituximab during early post-transplantation period does not decrease …
therapy using PE and rituximab during early post-transplantation period does not decrease …